endpoints

An­oth­er No­var­tis fail­ure; No­vo drops the ‘Nordisk’; and more

Welcome back to another edition of Endpoints Weekly! We’ll get to the headlines in just a bit, but be sure to check out the ...
endpoints

Post-Hoc Live: The Chi­na Biotech De­bate goes to Wash­ing­ton

Endpoints takes its China biotech debate to DC: four Post-Hoc Live conversations on patents, FDA data, biosecurity and ...
endpoints

All 50 states sign up for most fa­vored na­tion prices un­der Med­ic­aid, Trump says

All 50 states, DC and Puerto Rico join CMS' Generous model, tying Medicaid drug prices to what other wealthy countries pay.
endpoints

FDA ap­proves Lil­ly's oral SERD com­bo for sec­ond-line breast can­cer ther­a­py

The FDA ap­proved a new com­bi­na­tion reg­i­men from Eli Lil­ly for cer­tain breast can­cer pa­tients, a reg­i­men that in­cludes Lil­ly’s oral se­lec­tive es­tro­gen re­cep­tor de­grad­er (SERD) ...
endpoints

Chi­na sets am­bi­tious goals for glob­al drug and biotech ex­pan­sion in new five-year plan

China's new five-year plan targets 20% annual pharma revenue growth and a quarter of the world's first-in-class drugs by 2030 ...
endpoints

FDA says ini­tial re­jec­tions of new drugs have de­clined

An FDA report pushes back on claims it's rejecting more drugs, showing first-cycle rejection rates fell from 47% in 2008 to about 27% in 2024.
endpoints

An­throp­ic starts al­low­ing some life sci­ences re­searchers to use Mythos

Anthropic launched a Life Sciences Verification Program, granting select researchers access to AI models Mythos, Opus, and Sonnet, while maintaining biosafety restrictions on high-risk biological ...